16145-Renal Cancer-NA-445

Renal Cancer

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

  • Details

ClinicalTrials.gov ID: NCT02811861
Diagnosis Type: NA
USOR Number: 16145

  • Address

3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.